In addition to being a new Venture Associate at Al Hamra Group and focused on healthcare investments in the US, Julia is the founder and CEO of PuraCath Medical, a medical device company focused on improving efficacy of catheter connection to enhance the quality of life for both patients and healthcare providers. She has over twelve years of experience in R&D in medical device and biotech industries. Under her leadership, PuraCath Medical received FDA clearance for the Firefly® System, a peritoneal dialysis disinfection system to provide a safe and easy-to-use, self-contained PD catheter that does not rely on patient compliance. She is focused on revolutionizing the dialysis industry and bringing her novel home dialysis technology to make dialysis at home safer and more affordable. Prior to being the Founder and CEO of PuraCath Medical, she was a researcher at the renowned Molecular Imaging Laboratory at Stanford University School of Medicine, where she worked on stem cell therapy and imaging projects. Julia has obtained a B.Sc. in Bioengineering from the University of California Berkeley, an M.S. in Bioengineering from Stanford University, an M.S. in Medicine from Stanford University, and a Certificate from the Summer Institute for Entrepreneurship from the Stanford Graduate School of Business (GSB). She took a “leave‐of‐absence” from her PhD program in Bioengineering from Stanford University to grow PuraCath on a full-time basis. She has won multiple honors and awards, including the Howard Hughes Medical Institute Medical Scholar, the National Ford Foundation Pre-Doctoral Fellowship, the National Coca-Cola Scholarship, and multiple other governmental grants and awards for start-up ventures.